Search PubMed⌕ Search

Biomedical subjects

T Diamantstein

Publications and source records attributed to T Diamantstein.

At least 163 records · Page 9Linked to original sources

Interleukin 2 induces both, growth and maturation of lectin reactive Lyt-2+ but not Lyt-2-precursor cells and regulates the cytolytic potential of effector cells.

This study investigated the requirements for lymphokines derived by recombinant (rec.) DNA technology for the induction of growth and maturation in highly purified lectin reactive T cell subsets. Nylon purified C57BL/6 lymph node T cells were treated with monoclonal anti-Lyt-2.2 or anti-L3T4 antibodies and fluorescence labeled (FITC) anti-immunoglobulin antibodies and were positively selected into Lyt-2+ (L3T4-) and Lyt-2- (L3T4+) lymphocyte subsets using a fluorescence-activated cell sorter. Sorted T lymphocytes, which were devoid of accessory cells were incubated either in bulk culture (2 X 10(2) - 3 X 10(4) cells/microculture) or under limiting dilution conditions (2.5-1,000 cells/well) with lectin (Concanavalin A, Leukoagglutinin) and rec. human Interleukin 2 (rec. hIL-2) and/or rec. mouse Interferon gamma (rec. mIFN-gamma). The data show that Lyt-2+ lymphocytes respond to lectin and rec. hIL-2 with growth and development of cytolytic activity in the absence of other exogenous factor(s) or accessory cells. The presence of monoclonal antibodies to the Interleukin 2 receptor during the sensitization phase ablated the induction of Con A reactive precursor cells of cytolytic lymphocytes (CTL-P) by either rec. hIL-2 or conventional IL-2 containing lymphokine sources, indicating the essential role of IL-2 during activation of Lyt-2+ T lymphocytes. In contrast, Lyt-2- lymphocytes could not be induced by lectin and rec. hIL-2 alone for proliferation and always required the presence of accessory cells for significant growth. Exogenous rec. m IFN gamma was unable to induce growth and cytolytic activity in Con A reactive Lyt-2+ cells and did not significantly effect their response to rec. hIL-2. Limiting dilution experiments revealed that 10-16% of the Lyt-2+ lymphocytes responded to Con A and rec. hIL-2 with growth (GTL-P). The frequencies of CTL-P, determined under similar conditions, were always lower compared to GTL-P. However the results suggest that the differences observed between both precursor populations is due to differential sensitivity of the detection system rather than to the recruitment of distinct T cell subsets. Furthermore, it was shown that at least 50% of lectin reactive CTL-P were induced by rec. hIL-2 to secrete IFN-gamma under optimal conditions. The finding that some of the conventional lymphokine sources were superior to rec. hIL-2 in the induction of growth and cytolytic activity suggests the existence of mediators distinct from IL-2 that regulate the expansion of CTL-P.(ABSTRACT TRUNCATED AT 400 WORDS)

Agglutinins↗

Specific immunosuppressive therapy by monoclonal anti-IL 2 receptor antibody and its synergistic action with cyclosporin.

The effects of anti-IL 2R mab treatment on local GVHR and on heterotopic cardiac allograft survival in rats were investigated. Anti IL 2 mab inhibited specifically both GVHR as well as allograft rejection. IL 2R-targeted therapy was superior to that of anti-T helper/inducer cell treatment, as it did not affect T subset distribution and did not reduce the number of circulating T lymphocytes. This therapy when combined with a low subtherapeutic dose of CsA exerted a strongly synergistic effect. The results support the concept of IL 2R-targeted therapy in suppressing undesired immune reactions with limited side effects.

Animals↗

Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

The mouse hybridoma ART 18 monoclonal antibody (mAb), which binds to the rat interleukin 2 (IL-2) receptor, was studied for its effect on heterotopic cardiac allograft survival in two histoincompatible inbred rat strain combinations. Treatment with ART 18 mAb for 10 days after transplantation prolonged allograft survival in a dose-dependent fashion up to about 3 weeks (acute rejection normally occurs within 8 days). ART 18 mAb therapy started at 5 days after transplantation the time of major rejection activity) abrogated acute rejection and extended the survival to about 18 days. The dense cellular infiltrate noted histologically in acute rejection had virtually disappeared after ART 18 mAb treatment. Thus, IL-2 receptor-targeted therapy can be successfully used to prevent and/or treat acute rejection. When spleen cells from antibody-treated recipients bearing well-functioning allografts were adoptively transferred to normal untreated rats that received cardiac allografts 24 hr later, the survival of donor-specific, but not third-party, test cardiac allografts was prolonged significantly; this supports the idea that ART 18 mAb induced "sparing" of suppressor T lymphocytes. Combining infusion of ART 18 mAb with exogenous IL-2-rich conditioned medium produced the same effect as if the mAb alone had been administered, suggesting that an excess of IL-2 does not prevent binding of ART 18 mAb to IL-2 receptor-bearing cells in vivo. These results support the important role of the IL-2 receptor-bearing cells in the mechanism of allograft rejection; they may represent an important target for immunosuppression in clinical organ transplantation.

Animals↗

Development of suppressor lymphocytes during acute rejection of rat cardiac allografts and preservation of suppression by anti-IL-2-receptor monoclonal antibody.

Suppressor activity was investigated in rats undergoing acute rejection of heterotopic cardiac allografts. Spleen cells were harvested at 7 days from LEW rats rejecting (LEW x BN)F1 heart grafts and fractionated into their T, T suppressor/cytotoxic, and T helper subpopulations. Transfer of alloimmune unseparated spleen cells to syngeneic recipients of (Lew x BN)F1 test grafts accelerated rejection from 8 to 6.5 days (P less than 0.01). Graft survival was prolonged to about 15 days (P less than 0.005) after transfer of the splenic T suppressor/cytotoxic fraction. Treatment of test graft recipients with ART-18, a mouse antirat monoclonal antibody directed against the rat interleukin 2 receptor on the surface of activated lymphocytes, increased graft survival to about 3 weeks (P less than 0.005), and to about 23 days (P less than 0.005) when test graft recipients were treated with ART 18 following transfer of alloimmune unseparated spleen cells. In contrast, ART-18 treatment of test graft recipients already injected with T suppressor/cytotoxic cells had no additive effect. Increased production of endogenous interleukin 2 occurred concomitantly with the onset of rejection in these animals; interleukin 2 release declined during the late stages of rejection when suppressor activity had increased. Similarly, in T-cell-depleted (B) rats, allograft rejection could be produced by immune reconstitution with sensitized lymphocytes, but could be significantly delayed by prior transfer of suppressor cells. These data document the presence of potent suppressor activity in the acutely rejecting host and suggest that the suppressor mechanisms are inhibited less than effector mechanisms by interleukin-2-receptor-targeted therapy.

Animals↗

Regulation of interleukin 2 receptor expression by interleukin 2.

The regulatory influence of Interleukin 2 (IL-2) on the expression of IL-2 receptors (IL-2R) was studied using long-term cultured T-cell lines and recombinant IL-2 (r-IL-2). Three T-cell lines with different growth requirements were used as model systems: insulin-specific BK-BI-1.2 cells express IL-2R transiently after antigenic restimulation, ovalbumin-reactive BK-OVA-1R cells express IL-2R permanently, and BK-BI-2.6.C6 cells bear IL-2R constitutively but do not exhibit antigen reactivity. All three T-cell lines exhibited the property of increased IL-2R expression in the presence of r-IL-2, as tested by cytofluorometry employing monoclonal antibody AMT-13 directed at the murine IL-2R. IL-2R density was influenced selectively by r-IL-2, because the level of Thy-1.2 molecules was similar in the presence and absence of r-IL-2. With BK-BI-2.6.C6 cells, r-IL-2 was shown to upregulate high-affinity receptors. Since BK-BI-2.6.C6 and BK-OVA-1R cells were grown in the absence of feeder cells, these data show that r-IL-2 can regulate the expression of its own receptor without the participation of monokines. Results obtained with the T-cell line BK-BI-1.2, representing insulin-specific T cells with transient IL-2R expression, show that the presence of r-IL-2 did not prevent a decline in IL-2R density occurring on day 5 after antigenic stimulus. This indicates that additional mechanisms besides antigen- and IL-2-induced IL-2R upregulation are operative in controlling IL-2R density on the cell surface.

Animals↗

Synergistic action of gamma interferon and catalase to reverse the suppressive effect of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation.

The suppressive effect of normal rat peritoneal exudate cells (PEC) on concanavalin A (Con-A)-induced lymphocyte proliferation was studied. Partial suppression of proliferation was obtained by adding 3% PEC and complete suppression was observed with 6% PEC. The suppressive effect was mediated by W3/25+ plastic-adherent macrophages, which constitute about 60% of normal PEC. Addition of PEC prior to, simultaneously with, or 24 h after, but not 48 h after, the stimulation of lymphocytes with Con A resulted in suppression. Suppressed cultures produced normal or slightly increased amounts of interleukin 2 (IL-2), but the expression of the IL-2 receptor on lymphocytes was decreased. Pre-exposure of PEC to gamma interferon (IFN-gamma) resulted in decreased suppression, whereas IFN-gamma added simultaneously with the lymphocytes had no effect. Catalase reversed PEC-induced suppression and significant synergistic effects were recorded when combined with IFN-gamma. Even completely suppressed cultures were effectively protected from suppression. Indomethacin and combinations of indomethacin with catalase or IFN-gamma did not result in additional protection from PEC-mediated suppression.

Animals↗

The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antibodies.

In this report we have summarized our findings on the IL-2 receptor and our attempts to find an IL-2 receptor targeted immunosuppressive therapy. IL-2 receptors are detectable in two different forms: as monomeric, surface expressed, and as dimeric, presumably non-surface expressed molecules. The dimeric form seems to be non-covalently bound to an as yet undefined 110 KD molecule. The functions of the monomeric versus the dimeric form, as well as that of the noncovalently bound molecule, and their relationship to high and low affinity IL-2 receptors are not yet clear and remain to be elucidated. Upon antigenic or mitogenic stimulation, IL-2 receptors became expressed at the surface of T-lymphocytes. Receptor expression is accompanied by the capacity of the cells to proliferate in response to IL-2. Resting T-cells do not proliferate in response to IL-2. IL-2 dependent proliferation of cells without external stimulation is either due to the presence of a small number of IL-2 receptor bearing cells in the respective population or due to a small number of IL-2 receptors present on the surface of cells. IL-2 itself does not induce IL-2 receptor expression on resting cells but has been shown to up-regulate its own receptor once expressed. In contrast to resting lymphocytes, some leukemic cells and early embryonic thymocytes in the species tested constitutively express IL-2 receptors. The role of such constitutively expressed receptors is not yet clear. As demonstrated in mice, the requirement(s) for induction of IL-2 receptor expression for the helper/inducer subset (Lyt-2+) are different from those of the cytotoxic/suppressor subset (L3T4+). In contrast to Lyt-2+ cells, the accessory cell requirement for L3T4+ cells could not be replaced by cytokines. Whether Lyt-2+ cells require an additional, not yet defined receptor inducing factor (RIF) besides IL-2 in order to become IL-2 receptor positive and to consequently proliferate in response to IL-2, is a matter of controversy. There is evidence that interleukin-1 and some functionally related factors produced by leukemic cells enhance expression and/or function of the IL-2 receptors. IL-2 receptors of the high and low affinity type expressed upon antigenic stimulation are cleared from the cell surface. As demonstrated in this report, the vast majority of them, probably those of low affinity type, are released from the cells continuously. The mechanism of their release and the possible immunoregulatory role of circulating receptors found in the serum of animals is not yet clear.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

IL-2 normalizes defective suppressor T cell function of patients with systemic lupus erythematosus in vitro.

During autologous mixed lymphocyte reaction (AMLR) both helper and suppressor T cells capable of regulating B cell responses are generated. The proliferative response of T cells as well as the generation of T suppressor cells in the AMLR of patients with active systemic lupus erythematosus (SLE) is diminished. In contrast, the T helper cells generated in the AMLR show a hyperactivity. The diminished HLA-class II antigen expression observed on non-T cells of SLE origin was restored by treatment of the cells with gamma-interferon (gamma-IFN). When tested by immunoglobulin secretion, gamma-IFN enhanced T helper cell activity but failed to affect T cell proliferation and T suppressor cell generation in the AMLR derived from patients with SLE. Human recombinant interleukin 2 restores both the proliferative response of T cells and the induction of T suppressor cells in AMLR.

Adult↗

Cells reacting with the monoclonal anti-IL-2 receptor antibody AMT-13 in the regenerating thymus of irradiated mice.

The proportion and anatomical localization in murine thymus of T cell subpopulations, including those which are defined by the monoclonal anti-interleukin 2 (anti-IL-2) receptor antibody AMT-13, were studied by flow cytofluorometry and by immunohistochemical methods, both in irradiated and in normal mice. As a consequence of irradiation the proportion of AMT-13 positive cells and that of Lyt-1 positive cells were markedly enhanced, while the proportion of Lyt-2 positive cells was reduced. The vast majority of the AMT-13 positive cells both in normal and in irradiated thymi were located in the subcapsular area of the thymic cortex, whereas the irradiation resistant Lyt-1 positive cells were located in the medulla. These findings are compatible with the view that, similar to the developing thymus in the mouse embryo, in the regenerating adult thymus, AMT-13+ cells include the activated pro-thymocytes that repopulate the irradiated thymus.

Animals↗

Effects of in-vivo administration of a monoclonal antibody specific for the interleukin-2 receptor on the acute graft-versus-host reaction in mice.

Parental strain T lymphocyte injected into F1 mice respond to allogeneic MHC antigens and so induce the symptoms of a graft-versus-host reaction (GVHR). We have measured the local GVHR by the popliteal lymph node assay, and showed the suppression of the local GVHR in mice by treatment with the monoclonal antibody (MoAb) AMT-13 which is specific against the interleukin 2 (IL-2) receptor on activated mouse lymphocytes. The inhibitory effect of the AMT-13 administration was comparable with the suppression of the local GVHR by treatment with L3T4, an MoAb directed against the T helper subset. The L3T4 administration caused a dramatic decrease in the proportion of the cells with the L3T4 phenotype in the circulation and a marginal reduction of these cells in the lymph nodes. In contrast, the AMT-13 treated mice showed no changes in the distribution of the T lymphocyte subsets besides those in the GVHR-stimulated lymph nodes. Obviously, only the small subset of antigen-activated IL-2 receptor-bearing lymphocytes was influenced by treatment with AMT-13. MoAb directed against antigens whose expression is restricted to activated lymphocytes, such as the IL-2 receptor, might become useful for a short term immunosuppression with limited side effects.

Animals↗

Nucleotide sequence of mouse IL-2 receptor cDNA and its comparison with the human IL-2 receptor sequence.

We have cloned cDNA encoding the mouse interleukin-2 (IL-2) receptor from a murine T cell line, CTLL using human IL-2 receptor cDNA as probe. COS 7 cells transfected with the cDNA expressed the antigen recognized by the monoclonal antibody against the murine IL-2 receptor. The cDNA identified 4 species of mRNA (4.5, 3.5, 2.2 and 1.5 kb) of the mouse IL-2 receptor in CTLL cells. Difference in the length of mRNA seems to be ascribed to the variable length of the 3' untranslated sequence. Total nucleotide sequence (approximately 1400 bp) of this cDNA was determined and compared with the human receptor. The nucleotide and amino acid sequences of the IL-2 receptor are 70% and 60%, respectively, homologous in average between the two species. The comparison has revealed several conserved regions localized to particular exons such as transmembrane and cytoplasmic portions, suggesting that these regions are important for receptor function and its regulation.

Amino Acid Sequence↗

Direct demonstration that the monoclonal antibody AMT-13 and interleukin 2 bind to the same molecule.

125I-labeled surface molecules from mouse T lymphoblasts were fractionated by affinity supports coupled with recombinant interleukin 2 (IL2) and the monoclonal antibody (mAb) AMT-13. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis demonstrated that two molecules of approximately 55 kDa and of approximately 180 kDa were bound in both cases. Sequential precipitation and SDS-PAGE analysis of the precipitated molecules revealed that only the approximately 55-kDa molecule eluted from AMT-13 mAb support was rebound to IL2 affinity support. In addition, IL2 inhibited specifically the binding of 125I-labeled AMT-13 mAb to T lymphoblasts. Thus the results directly demonstrate that the a approximately 55-kDa cell surface molecule represents the IL2-binding protein and that the mAb AMT-13 reacts with this molecule.

Animals↗

Expression of interleukin 2 receptor on murine fetal thymocytes.

Rat monoclonal antibodies AMT-13, 3C7 and 7D4 which react to the mouse interleukin 2 (IL 2) receptors were used to define cell populations with the putative IL 2 receptors in the mouse thymus as a part of series of investigations to elucidate the mechanism of intrathymic cell proliferation and differentiation. With freshly dissociated cells from the thymus of 15 gestational days, the anti-IL 2 receptor monoclonal antibodies (anti-IL 2 receptor) reacted with about half of them. The proportion of the reactive cells decreased rapidly thereafter till birth as the numbers of thymus cells expanded. The antibodies reacted with only two to three percent of thymic cells from newborn mice and less than one percent of cells from adult thymus. Through the gestational period, the fetal liver cells did not react with the antibodies. When the thymus cells at early gestational days were subjected to a two-color analysis, one for the anti-IL 2 receptor and the other for anti-Thy-1 or anti-asialo GM1, by a fluorescence-activated cell sorter, it was found that the majority (up to 80%) of anti-IL 2 receptor-reactive cells (IL 2 receptor-positive cells) was also reactive with anti-Thy-1. Some of the IL 2 receptor-positive cells but Thy-1-negative cells reacted with anti-asialo GM1, a marker of the immature thymocytes. Immunohistochemically, the IL 2 receptor-positive cells were found mainly in the subcapsular area and in the border region of cortex and medulla. Collectively, these results suggest that the pre-T lymphocytes are stimulated immediately after their arrival to the thymus from the stem cell source such as fetal liver and bone marrow and are driven into the proliferation via the IL 2 receptor system.

Animals↗

Signal requirements for the in vitro differentiation of cytotoxic T lymphocytes (CTL): distinct soluble mediators promote preactivation of CTL-precursors, clonal growth and differentiation into cytotoxic effector cells.

We describe here that the requirement of accessory cells for the polyclonal activation of high-density (resting) murine T lymphocytes can be bypassed by soluble mediators present in culture supernatants of concanavalin A (Con A)-activated murine spleen cells. Induction of responsiveness is confined to Lyt-2+ T cells; GK 1.5+ T helper cells require signals provided by accessory cells. Using this system the lymphokine signal requirements for the polyclonal activation of Lyt-2+ cytotoxic T lymphocyte (CTL) precursors could be defined. We show that Con A fails to trigger in Lyt-2+ responder T cells the expression of interleukin 2 (IL 2) receptors and assume that this explains why recombinant (rec) DNA-derived IL 2 fails to induce proliferative responses. Complementation of rec IL 2 with an IL 2 receptor-inducing factor (RIF) induces proliferative responses. RIF alone triggers IL 2 receptor expression in 10-12% of Lyt-2+ T cells exposed to Con A. This lymphokine appears to be distinct from colony-stimulating factor 1, IFN-gamma and IL 1. Resting Lyt-2+ T cells cultured in limiting numbers in the presence of Con A, RIF plus rec IL 2 do proliferate, yet exhibit no cytolytic activity. Differentiation into CTL can be brought about by addition of cytotoxic T cell differentiation factor (CTDF). We conclude that the polyclonal activation pathway of CTL from resting CTL precursors can be subdivided into three stages: preactivation, clonal growth and CTL differentiation. Each of these stages appears to be controlled by a distinct lymphokine, RIF, IL 2 and CTDF, respectively.

Animals↗

The mode of action of the calcium ionophore A23187 on T cell proliferation. I. The ionophore does not replace lymphokines but acts via induction of IL-2 production on IL-2 responsive cells.

The two compounds, the calcium ionophore A23187 and phorbol myristate acetate (PMA), which are not mitogenic for mouse thymocytes, induce proliferation when added in combination to thymocyte cultures. Short exposure to PMA renders the cells responsive to IL-2, added exogeneously. The cells rendered IL-2-responsive by PMA are enriched in the more mature peanut agglutinin (PNA)-negative population. The ionophore does not render PNA-negative thymocytes IL-2-responsive, but induces proliferation of PMA-pulsed PNA-negative thymocytes. PMA-pulsed PNA-negative thymocytes proliferating in response to either exogeneous IL-2 or ionophore express IL-2 receptors. However, the ionophore does not mimic IL-2 action but acts indirectly by induction of both IL-2 production and of IL-2 receptor expression via IL-2. This view is based on the following findings: 1) IL-2 could be detected in supernatants derived from PMA-preactivated thymocytes incubated with the ionophore; 2) The IL-2-induced proliferation, as well as the ionophore-induced proliferation, was specifically blocked by a monoclonal anti-IL-2-receptor antibody; 3) The proliferation induced by exogeneous IL-2, as well as that induced by the ionophore, could be specifically inhibited by metabolically blocked T lymphoblasts carrying IL-2 receptors competing with the responder cells for the available IL-2 added or produced in the system.

Animals↗

Studies on interleukin 2 receptor expression and IL-2 production by murine T cell lymphomas.

In order to study the possible role of the T-lymphocyte growth factor, Interleukin 2 (IL-2), and/or of the IL-2 receptor in the autonomous growth of leukaemic cells, 15 mouse leukaemic cell lines of various aetiology were analyzed for (i) IL-2 receptor expression and (ii) for the capacity to secrete IL-2. Several but not all of the cell lines tested were IL-2 receptor positive. The cells constitutively expressing IL-2 receptors at their surface could not be stimulated to secrete IL-2. Cell producing and secreting IL-2 did not express detectable amounts of IL-2 receptors at their surface. It has been demonstrated that proliferation of the leukaemic cells was independent of exogenous IL-2. The monoclonal anti-IL-2 receptor antibody AMT-13 inhibited IL-2 dependent proliferation of activated normal T-lymphocytes but failed to inhibit the growth of IL-2 receptor expressing leukaemic cells. The results argue against the autocrine stimulation hypothesis but do not exclude the possibility of involvement of functionally altered IL-2 receptors on autonomous cell growth.

Animals↗

Production of Listeria-specific rat T-cell clones and role of interleukin-2 receptors in regulation of Listeria-dependent T-cell clone growth in vitro.

Splenic T lymphocytes from rats immunized with the facultative intracellular bacterium Listeria monocytogenes were cloned by the limiting-dilution technique in the presence of accessory cells, heat-killed L. monocytogenes as antigen, and conditioned medium containing interleukin-2. The cloned rat T-cells were Listeria-specific cells, and their proliferation depended on class II-restricted antigen presentation by accessory cells. As demonstrated by their reactivity to the monoclonal antibody W3/25, the clones were of helper cell phenotype. Cloned-cell proliferation depended on repeated (or continuous) exposure to antigen. When antigen was omitted from the system, cell growth subsided over time, and cells finally ceased to grow. By the use of the monoclonal antibody ART-18, which recognizes the interleukin-2 receptor, it was shown that cessation of growth was accompanied by the disappearance of interleukin-2 receptors from the cell surface. The addition of antigen to the culture resulted in the reexpression of interleukin-2 receptors and concomitant resumption of proliferation.

Animals↗